385
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

In vitro and in vivo Antimicrobial Activities of Ceftazidime/Avibactam Alone or in Combination with Aztreonam Against Carbapenem-Resistant Enterobacterales

, , , , , , , ORCID Icon & ORCID Icon show all
Pages 7107-7116 | Received 05 Aug 2022, Accepted 23 Nov 2022, Published online: 05 Dec 2022

References

  • Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Di. 2019;38(12):2275–2281. doi:10.1007/s10096-019-03673-1
  • Seo H, Lee SC, Chung H, et al. Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Enterobacteriaceae bacteremia. Int J Antimicrob Agents. 2020;56(4):106126. doi:10.1016/j.ijantimicag.2020.106126
  • Sun J, Wang B, Warden AR, et al. Overcoming multidrug-resistance in bacteria with a two-step process to repurpose and recombine established drugs. Anal Chem. 2019;91(21):13562–13569. doi:10.1021/acs.analchem.9b02690
  • Seok H, Choi JY, Wi YM, et al. Fosfomycin resistance in Escherichia coli isolates from South Korea and in vitro activity of fosfomycin alone and in combination with other antibiotics. Antibiotics. 2020;9(3):112. doi:10.3390/antibiotics9030112
  • Isber C, Stockman DL, Daoud Z. Quadruple-checkerboard: a modification of the three-dimensional checkerboard for studying drug combinations. J Vis Exp. 2021;173:e62311.
  • Zhang W, Guo Y, Li J, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2018;7(1):142. doi:10.1186/s13756-018-0435-9
  • Richter SN, Frasson I, Bergo C, et al. Transfer of KPC-2 Carbapenemase from Klebsiella pneumoniae to Escherichia coli in a patient: first case in Europe. J Clin Microbiol. 2011;49(5):2040–2042. doi:10.1128/JCM.00133-11
  • Bleichenbacher S, Stevens M, Zurfluh K, et al. Environmental dissemination of carbapenemase-producing Enterobacteriaceae in rivers in Switzerland. Environ Pollut. 2020;265(Pt B):115081. doi:10.1016/j.envpol.2020.115081
  • Suay-Garcia B, Perez-Gracia MT. Present and future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics. 2019;8(3):122. doi:10.3390/antibiotics8030122
  • Han R, Shi Q, Wu S, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314. doi:10.3389/fcimb.2020.00314
  • Veeraraghavan B, Shankar C, Karunasree S, et al. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience. Pathog Glob Health. 2017;111(5):240–246. doi:10.1080/20477724.2017.1340128
  • Galani I, Karaiskos I, Karantani I, et al. Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Euro Surveill. 2018;23(31). doi:10.2807/1560-7917.ES.2018.23.30.1700775
  • Maraki S, Mavromanolaki VE, Moraitis P, et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-beta-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755–1759. doi:10.1007/s10096-021-04197-3
  • Meini S, Viaggi B, Tascini C, Mono V. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature. Infection. 2021;49(3):411–421. doi:10.1007/s15010-021-01577-x
  • Hakeam HA, Alsahli H, Albabtain L, et al. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis. 2021;109:1–7. doi:10.1016/j.ijid.2021.05.079
  • Di Pilato V, Aiezza N, Viaggi V, et al. KPC-53, a KPC-3 variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam. Antimicrob Agents Chemother. 2020;65(1):e01429. doi:10.1128/AAC.01429-20
  • Li D, Liao W, Huang H, et al. Emergence of hypervirulent ceftazidime/avibactam-resistant Klebsiella pneumoniae isolates in a Chinese tertiary hospital. Infect Drug Resist. 2020;13(2673–2680). doi:10.2147/IDR.S257477
  • Wang Y, Wang J, Wang R, et al. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18–27. doi:10.1016/j.jgar.2019.12.009
  • Wenzler E, Deraedt MF, Harrington AT, et al. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens. Diagn Microbiol Infect Dis. 2017;88(4):352–354. doi:10.1016/j.diagmicrobio.2017.05.009
  • Yao H, Liu J, Jiang X, et al. Analysis of the clinical effect of combined drug susceptibility to guide medication for carbapenem-resistant Klebsiella pneumoniae patients based on the Kirby-Bauer disk diffusion method. Infect Drug Resist. 2021;14:79–87. doi:10.2147/IDR.S282386
  • Falcone M, Menichetti F, Cattaneo D, et al. Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. J Antimicrob Chemother. 2021;76(4):1025–1031. doi:10.1093/jac/dkaa549
  • Yasmin M, Fouts DE, Jacobs MR, et al. Monitoring ceftazidime-avibactam and aztreonam concentrations in the treatment of a bloodstream infection caused by a multidrug-resistant Enterobacter sp. carrying both Klebsiella pneumoniae Carbapenemase–4 and New Delhi Metallo-β-Lactamase–1. Clin Infect Dis. 2020;71(4):1095–1098. doi:10.1093/cid/ciz1155
  • Vena A, Giacobbe DR, Castaldo N, et al. Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales. Antibiotics. 2020;9(2):71. doi:10.3390/antibiotics9020071
  • Cultrera R, Libanore M, Barozzi A, et al. Ceftolozane/tazobactam and ceftazidime/avibactam for multidrug-resistant gram-negative infections in immunocompetent patients: a single-center retrospective study. Antibiotics. 2020;9(10):640. doi:10.3390/antibiotics9100640
  • Nwankwo L, Butt Z, Schelenz S. Experience of Ceftazidime/avibactam in a UK tertiary cardiopulmonary specialist center. Expert Rev Anti Infect Ther. 2021;19(1):101–108. doi:10.1080/14787210.2020.1810568
  • Kuang H, Zhong C, Wang Y, et al. Clinical characteristics and outcomes of patients with multidrug-resistant Gram-negative bacterial infections treated with ceftazidime/avibactam. J Glob Antimicrob Resist. 2020;23:404–407. doi:10.1016/j.jgar.2020.10.023
  • Castanheira M, Mills JC, Costello SE, et al. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains. Antimicrob Agents Chemother. 2015;59(6):3509–3517. doi:10.1128/AAC.00163-15